Reg. Name:

Opdivo®,

Class:

PD-1 inhibitor

Adapted from Sundar R. et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar; 7(2): 85-96. doi: 10.1177/175884014567470.

Disclaimer: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.